What can be said about IPS Therapeutique?

IPS Therapeutique is a specialty Contract Research Organization which dedicates its expertise and technology to the evaluation of the cardiac safety of new drugs at an early stage of their development, by using validated and highly predictive models.

Recognized for the quality and the on-time delivery of its IND enabling studies, IPS Therapeutique addresses the particular needs of start-up and mature biopharmaceutical companies which are looking for fast and cost-effective solutions to assess the QT Prolongation and the arrhythmogenic liability of their new compound(s) during preclinical development.


IPST's commitment
Our strongest commitment is to stay ahead of regulatory expectations by leveraging the most promising and innovative scientific discoveries that offer true benefits in their predictive value in humans.

We strongly believe our holistic assessment of cardio-vascular safety pharmacology successfully contributes to the faster development of safer medicines, leading to substantial economy of human and material resources for all.



Company profile & history

IPST was founded in 1999 in response to the rising concerns from the international community about the safety of existing drugs and new chemical entities.

From these early days, our scientists have been developing methods for the assessment of the arrhythmogenic potential of drugs through the use of applied electrophysiological techniques on in-vitro cellular and tissular models. Located in state-of-the-art facilities, IPST is in a strategic position to meet the growing and challenging needs of the pharmaceutical industry.

Click here for more